Skip to content
GERICLINICS

GeriQBank · Paper III · Q2

Etiopathogenesis, clinical presentation and management of the Parkinson-plus syndromes in older adults

Moderate YieldAsked ×115-mark essay
Topic
Parkinsonism & Movement Disorders
Chapter
Parkinson's Disease & Movement Disorders
Years asked
Not recorded in the source
Frequency
Set 1× in Paper III (2009–2025)

As set in the university paper

  • Etiopathogenesis, clinical presentation and management of the Parkinson-plus syndromes in older adults.

    Paper III · Parkinson’s Disease & Movement Disorders · asked ×1 · 15-mark essay · see in paper list

Answer framework

  1. Definition and importance — atypical parkinsonism; share in very late onset; levodopa response; synucleinopathies and tauopathies
  2. The individual syndromes (Pathy Table 53.2) — common in very late onset; rare in very late onset
  3. Key distinctions — DLB criteria and the timing rule; neuroleptics in AD; PSP midbrain; vascular parkinsonism; NPH gait
  4. Diagnostic approach — history and drugs; DaTSCAN, MRI and eye movements; follow-up
  5. Management — levodopa trial; drug-induced parkinsonism; avoid anticholinergics; prevention; supportive care; no DBS; prognosis
  6. Recent updates — MSA criteria; α-synuclein seeding and skin biopsy; PSP variants and tau PET; global PSP; DLB in biological frameworks; therapeutics

An exam answer plan drawn from the detailed answer below. Use it to attempt the question first.

Detailed answer

Pro · free in beta
Attempt it firstOutline your answer as a 15-mark essay before revealing it — definition, causes, evaluation, management and the geriatric angle.Reveal answer

Short revision answer

  • Parkinson-plus (atypical parkinsonism) = parkinsonism with extra neurological features not explained by PD, and poor levodopa response — the single best discriminator. In very late-onset parkinsonism, 20–40% of new cases are not idiopathic PD. Causes: synucleinopathies (MSA, DLB), tauopathies (PSP, CBD) and non-degenerative causes (drugs, vascular, hydrocephalus).
  • Common in very late onset: drug-induced (neuroleptics; dyskinesia, no tremor, normal DaTSCAN); DLB (dementia within months, hallucinations, neuroleptic sensitivity, fluctuation, falls); AD (parkinsonism in ~15%, late and mild); PSP (early falls, axial rigidity, vertical gaze limitation, neck dystonia, no tremor, midbrain atrophy); cerebrovascular (infarcts, worsening after strokes, pseudobulbar signs); NPH (gait, incontinence, slowing, ventriculomegaly).
  • Rare in very late onset: MSA (early severe dysautonomia — orthostatic hypotension, bladder, sexual and GI symptoms — with pyramidal or cerebellar signs); CBD (dystonia, myoclonus, sensory loss, alien hand); Huntington's (chorea); Wilson's (liver disease, Kayser–Fleischer ring); toxic and post-encephalitic causes.
  • DLB: dementia plus hallucinations, extrapyramidal signs, fluctuation, falls or neuroleptic intolerance; dementia within months of parkinsonism = DLB, after years = PD dementia. In AD, extrapyramidal signs may reflect past neuroleptics and predict faster decline. PSP shows a convex (atrophic) midbrain. Vascular parkinsonism starts or worsens within a month of a stroke, with gait and swallowing problems, little tremor and poor levodopa response. NPH gait has no tremor or rigidity and doesn't respond to cues or levodopa.
  • Diagnosis: history and examination (with an exhaustive drug history) usually suffice; DaTSCAN separates degenerative parkinsonism from essential tremor, drug-induced parkinsonism and AD; MRI shows midbrain atrophy, vascular lesions or hydrocephalus; ocular electrophysiology supports PSP; follow-up clarifies the rest.
  • Management: an adequate levodopa trial in every case (a clear negative response is diagnostic, and some patients benefit partially). Drug-induced: stop the drug — recovery takes weeks to months, ~20% keep some signs (unmasked degeneration), and tardive dyskinesia may be permanent; neuroleptics for dementia behaviour are ineffective anyway — switch to a low-dose atypical if psychosis must be treated. Never use anticholinergics; prevent by avoiding neuroleptics in older people.
  • Supportive care: falls prevention and physiotherapy, speech and swallow therapy, treatment of orthostatic hypotension (droxidopa, midodrine, fludrocortisone, stockings), botulinum toxin for drooling, carer education and advance planning; DBS is not indicated. Atypical syndromes progress faster, with early falls, dysphagia, dependency and death from aspiration.
  • Updates: the MDS MSA criteria (2022) define four certainty levels including possible prodromal MSA (validated 2023, improved by MRI markers); α-synuclein seed amplification distinguishes strains, and skin biopsy for phospho-α-synuclein is emerging (PD specificity up to 100%, sensitivity up to 81%) — not yet routine in India.
  • MDS-PSP criteria define eight variants and a "suggestive of PSP" category (validated 2025); second-generation tau PET (18F-PI-2620) detects 4-repeat tau; NfL and GFAP track progression; PSP prevalence is 5–6.4 per 100,000. NSD-ISS and SynNeurGe (2024) treat PD and DLB as one α-synuclein continuum for research. No disease-modifying therapy exists (tau agents for PSP and TEV-56286 for MSA are in trials).

Condensed by GeriClinics from the detailed answer below, with no new facts added.

High-Yield Points (Textbook)

Source: Pathy's 6th ed., Chapter 53 (Tables 53.2, Box 53.1) and Chapter 46; Essentials of Clinical Geriatrics 7th ed.

Definition and importance

1.

Parkinson-plus (atypical parkinsonism) means an extrapyramidal syndrome accompanied by additional neurological features not explained by idiopathic PD, with a poor response to levodopa.

2.

These are disproportionately important in geriatrics: in very late-onset parkinsonism, non-PD causes account for 20–40% of all new parkinsonism in the elderly, a much higher proportion than in early-onset disease.

3.

Poor levodopa response is the single most useful clinical discriminator, assessed from history or by formal levodopa challenge (Box 53.1).

4.

Etiopathogenesis divides into synucleinopathies (multiple system atrophy, dementia with Lewy bodies) and tauopathies (progressive supranuclear palsy, corticobasal degeneration), alongside non-degenerative causes (drug-induced, vascular, hydrocephalic). Clinical presentation of the individual syndromes (Pathy's Table 53.2)

Condition Characteristic features

Frequently observed as very late-onset parkinsonism Drug-induced parkinsonism Exposure to neuroleptics or other drugs before onset. Dyskinesia frequent, no tremor. Ioflupane SPECT normal. Lewy body dementia Dementia within a few months before or after onset of parkinsonism; hallucinations; severe adverse reactions to neuroleptics; fluctuating course; falls.

Alzheimer's disease Parkinsonism infrequent (about 15%), only at moderate/severe stages and usually mild. Hippocampal atrophy on MRI; SPECT normal.

Progressive supranuclear palsy Early postural instability and repeated falls; axial rigidity; limitation of vertical gaze; neck dystonia; impaired saccades on ocular electrophysiology. No tremor. MRI: midbrain atrophy.

Cerebrovascular disease Parkinsonism with several infarcts on MRI, worsening after infarction; multilacunar state, pseudobulbar syndrome, emotional lability, pyramidal signs, vascular dementia.

Normal pressure hydrocephalus Gait disturbance, urinary incontinence, cognitive slowness. Marked ventricular enlargement not explained by atrophy. Very rarely observed as very late-onset parkinsonism Multiple system atrophy Severe dysautonomia early in the course — orthostatic hypotension, urinary disorder, sexual dysfunction, gastrointestinal symptoms — with pyramidal or cerebellar syndrome.

Corticobasal degeneration Dystonia, myoclonus, sensory disorders, alien ("foreign") hand syndrome. Huntington's disease Chorea; familial cases.

Wilson's disease Liver disease, complex neurological signs including parkinsonism, psychiatric symptoms, familial cases, Kayser– Fleischer ring.

Miscellaneous Toxic; post-encephalitic; repeated skull trauma.

5.

Dementia with Lewy bodies is strongly related to PD, sharing Lewy body and α-synuclein pathology. Diagnosis needs (i) cognitive dysfunction fulfilling dementia criteria with insidious onset and progression, plus (ii) one or more of hallucinations, extrapyramidal syndrome, fluctuating course, falls and poor tolerance of neuroleptics. Extrapyramidal signs may precede cognitive decline by months.

6.

Key timing rule: dementia within a few months of parkinsonism = DLB; dementia after several years of established PD = PD-related dementia.

7.

In Alzheimer's disease, extrapyramidal signs may reflect current or past neuroleptic exposure — this must be sought by interviewing patients, proxies, physicians and pharmacists. Their presence at diagnosis predicts more rapid decline.

8.

PSP is frequently misdiagnosed as PD. Cerebral MRI shows a convex midbrain outline indicating atrophy, where the normal midbrain aspect is concave.

9.

Vascular parkinsonism: onset or worsening of extrapyramidal signs within one month after a stroke strongly supports the diagnosis. Swallowing problems and gait/posture abnormality are frequent; tremor infrequent; levodopa response poor. MRI shows multiple lacunae and/or severe leukoaraiosis.

10.

NPH gait can mimic PD (short steps, shuffling, slowness, stooped trunk, flexed lower limbs) but there is no tremor and no rigidity, and the gait does not respond to external cues or to levodopa. Imaging shows quadriventricular dilatation with small sulci and periventricular T2 high signal.

Diagnostic approach

11.

In most cases medical history and physical examination alone allow identification; the drug history must be exhaustive.

12.

Ioflupane (DaTSCAN) SPECT separates degenerative parkinsonism (abnormal) from essential tremor, drug-induced parkinsonism and Alzheimer's disease (normal). MRI identifies midbrain atrophy, vascular lesions and hydrocephalus. Ocular electrophysiology supports PSP.

13.

Where doubt persists, follow-up usually clarifies the diagnosis as new signs and symptoms emerge.

Management

14.

Give an adequate trial of levodopa in every case — a clear negative response is itself diagnostically useful, and some patients obtain partial benefit.

15.

Drug-induced parkinsonism: stopping the offending drug is the best option. Recovery is very slow, over weeks to months, and in about 20% some extrapyramidal signs persist, suggesting underlying PD or another neurodegenerative parkinsonism unmasked by the drug. Tardive dyskinesia is often permanent even after withdrawal. There is no satisfactory drug treatment.

16.

In elderly patients this withdrawal is usually possible, because neuroleptics are mainly used for behavioural complications of dementia — a condition for which they are ineffective. If severe psychosis demands treatment, switch from a classical neuroleptic to a low-dose atypical antipsychotic.

17.

Anticholinergics must be avoided in the elderly — they induce delirium and other adverse effects.

18.

Prevention of drug-induced parkinsonism is a crucial issue in geriatric care, achieved by avoiding neuroleptic prescription in older people, especially those with dementia.

19.

Supportive and symptomatic care dominates management: falls prevention and physiotherapy, speech and swallow therapy, treatment of orthostatic hypotension (droxidopa, midodrine, fludrocortisone, elastic compression), botulinum toxin for drooling, carer education and advance care planning. DBS is not indicated in Parkinson-plus syndromes.

20.

Prognosis: atypical syndromes progress faster than PD, with earlier falls, dysphagia, dependency and death, usually from aspiration pneumonia.

Latest Updates (2023–Present)

MSA — new criteria and validation. The MDS criteria for MSA (Wenning et al., Mov Disord 2022) replaced the 2008 consensus and define four certainty levels: neuropathologically established, clinically established, clinically probable, and possible prodromal MSA. Brain-bank validation confirmed improved early sensitivity (Sekiya et al., Neurology 2023); adding MRI markers further improves performance (Mov Disord 2024). α-Synuclein seeding biomarkers. Lancet Neurology 2024 (MSA review) highlights disease-specific α-synuclein strains distinguishable by seed amplification assay. Skin biopsy for phosphorylated α-synuclein is emerging — specificity for PD up to 100%, sensitivity up to 81%, and fibrillar phospho-α-synuclein in Schwann cells appears to be an MSA-specific hallmark (Donadio et al.; Gibbons et al., Neurology 2023). Skin SAA is being evaluated to separate MSA from PD (2025–26 data). These remain promising but incompletely validated, and are not in routine Indian practice. PSP — expanded phenotype. The MDS-PSP criteria define eight clinical variants across four functional domains and include a "suggestive of PSP" category for early disease; this category was prospectively validated (Quattrone et al., Mov Disord 2025). Second-generation tau-PET (18F-PI-2620) detects 4-repeat tau in the basal ganglia and predicts increasing diagnostic certainty; plasma/CSF NfL and GFAP on SIMOA track progression (Brain Communications 2025).

Global and Indian perspective on PSP. A 2026 global review in Movement Disorders Clinical Practice (Kukkle et al.) reports prevalence 5–6.4 per 100,000, with regional variation in the MAPT H1 haplotype, dietary neurotoxins and industrial pollutants, and marked differences in access to specialist care.

DLB within the biological framework. Both the NSD-ISS and SynNeurGe systems (Lancet Neurology 2024) explicitly cover PD and DLB as one α-synuclein-driven biological continuum, formally dissolving the arbitrary "one-year rule" for research purposes — though the clinical rule is still examined.

Therapeutics. There is still no disease-modifying therapy for any Parkinson-plus syndrome. Tau-directed agents (antibodies, antisense oligonucleotides, sodium selenate) are in trial for PSP; TEV-56286 (OGA inhibitor) is in Phase 2 for MSA.

Current Practice Update

Aspect Textbook position Current evidence-based practice MSA diagnosis Clinical — early severe dysautonomia with MDS 2022 criteria with four certainty levels including pyramidal or cerebellar signs possible prodromal MSA; MRI markers formally incorporated PSP diagnosis Single phenotype: gaze palsy, early falls, axial MDS-PSP criteria — eight variants (PSP-RS, PSP-P, rigidity, midbrain atrophy PSP-PGF, PSP-CBS and others) with an early "suggestive of PSP" category Confirmatory testing Ioflupane SPECT, MRI, ocular electrophysiology Add α-synuclein SAA (CSF and skin) and tau-PET (18F-PI-2620) — research/tertiary use; MRI plus autonomic testing remain the routine tools DLB vs PD dementia Separated by the one-year timing rule Clinically retained; biologically both are classed as neuronal α-synuclein disease in the 2024 research frameworks Treatment Symptomatic; levodopa trial; avoid neuroleptics Unchanged — no disease-modifying therapy exists; tau-and synuclein-directed trials ongoing Examiner's Tip — lines that earn marks Open with the geriatric statistic: "In very late-onset parkinsonism, 20–40% of new cases are not idiopathic PD." State the discriminator: "Parkinsonian syndromes other than PD respond poorly to levodopa." Give the one-line signature of each: MSA = early severe dysautonomia; PSP = early falls + vertical gaze palsy + axial rigidity + midbrain atrophy; CBD = alien hand, myoclonus, dystonia; DLB = dementia within months + hallucinations + neuroleptic sensitivity; vascular = worsening within one month of stroke; NPH = gait + incontinence + cognitive slowing with ventriculomegaly. Score the geriatric point: "Prevention of drug-induced parkinsonism by avoiding neuroleptics in dementia is a crucial issue in geriatric care — 20% have persistent signs even after withdrawal."

How was your recall?

Rating marks the question complete. “Need another pass” also adds it to your bookmarks.

References

Spotted an error or something out of date?Report a problem with this page